Fundraising FoxProMIS Neurosciences
Toronto, CA · Canada (Federal Level) corporation · 2 known investors
Find your way into ProMIS Neurosciences
Each arrow is one introduction. Sign up to fill in the first one.
210 people can intro you to EUGENE
Ask Cristina Csimma to introduce you to EUGENE WILLIAMS
You →Cristina · together at Akashi Therapeutics, Inc. →EUGENE
171 people can intro you to Neil
Ask Jamie Chen to introduce you to Neil K. Warma
You →Jamie · together at I-Mab Biopharma →Neil
Sign up to find every way you can get introduced to ProMIS Neurosciences
- Your email: who you already know at ProMIS Neurosciences, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the ProMIS Neurosciences team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
ProMIS Neurosciences is a clinical-stage biotechnology company developing antibody therapeutics that target toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's, ALS, and Parkinson's. The company operates in the biotechnology and neurology therapeutics space.
Founders & leadership
NC
Neil Cashman, M.D.Chief Scientific Officer and Co-founder
EW
EUGENE WILLIAMSChairman and Co-FounderHe currently serves as CEO of Autoimmunity BioSolutions, and previously led Akashi Therapeutics as Chairman and CEO from 2010 to 2014. He also advised Red Sky Partners and sat on the board of the Muscular Dystrophy Association from 2018 to 2022.
RG
ROBERT GUNDELExecutive
NK
Neil K. WarmaPresident and Chief Executive OfficerNeil K. Warma has over 25 years of experience in biotechnology, including founding and building biotech companies, restructuring operations, executing M&A transactions and IPOs, and holding leadership roles in multinational pharmaceutical companies across Asia, Europe, and North America. He is President and Chief Executive Officer of ProMIS Neurosciences, a clinical-stage biotechnology company developing antibody therapeutics for neurodegenerative diseases.
EG
ELLIOT GOLDSTEINNamed on SEC filing
WW
WARREN WHITEHEADNamed on SEC filing
PK
PATRICK KIRWINNamed on SEC filing
NC
NEIL CASHMANNamed on SEC filing
WW
WILLIAM WYMANNamed on SEC filing
JM
JOHANNES MINHO ROTHNamed on SEC filing
Board
HB
HANS BLACKBoard director
Investors · 2
Funding
SEC filings, press & company announcements$38.3M disclosed across 21 of 22 rounds · 2012–2026
- Undisclosed amountPIPE financingJan 2026Source ↗
▶$7.5MraisedOct 2022 · 23 investors · BiotechnologyRule 506(b)
▶$7.5MraisedOct 2022 · 23 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard GregoryDirector
- Daniel GeffkenExecutive Officer
- Eugene WilliamsDirector
- Josh Mandel-BrehmDirector
- Larry AltstielExecutive Officer
- William WymanDirector
- Neil CashmanExecutive Officer, Director
- Gavin T. MalenfantExecutive Officer
- Gail M. FarfelExecutive Officer
- Neil K. WarmaDirector
- Patrick KirwinDirector
- Maggie ShafmasterDirector
- Offering amount
- $10.1M
- Amount sold
- $7.5M
- Minimum investment
- $27K
- Sales commissions
- $597.8K
- Placement agents
- CEROS FINANCIAL SERVICES, INC.
- First sale
- Oct 2022
- Incorporated
- Corporation, Canada (federal Level)
- Federal exemptions
- 06b
▶$18.1MraisedSep 2021 · 34 investors · BiotechnologyRule 506(b)
▶$18.1MraisedSep 2021 · 34 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- William WymanDirector
- Elliot GoldsteinExecutive Officer
- Daniel GeffkenExecutive Officer
- Patrick KirwinDirector
- Johanne KaplanExecutive Officer
- Richard GregoryDirector
- Neil CashmanExecutive Officer, Director
- Eugene WilliamsExecutive Officer, Director
- Offering amount
- $24.7M
- Amount sold
- $18.1M
- Sales commissions
- $12.7M
- Placement agents
- Ceros Financial Services, Inc.
- First sale
- Aug 2021
- Incorporated
- Corporation, Canada (federal Level)
- Federal exemptions
- 06b
▶$7MraisedMar 2021 · 7 investors · BiotechnologyRule 506(b)
▶$7MraisedMar 2021 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Elliot GoldsteinExecutive Officer, Director
- Eugene WilliamsExecutive Officer, Director
- William WymanDirector
- Patrick KirwinDirector
- Neil CashmanExecutive Officer, Director
- Richard GregoryDirector
- Steven PlotkinExecutive Officer
- Daniel E. GeffkenExecutive Officer
- Johanne KaplanExecutive Officer
- Offering amount
- $7M
- Amount sold
- $7M
- First sale
- Mar 2021
- Incorporated
- Corporation, Canada (federal Level)
- Federal exemptions
- 06b
▶$63KraisedNov 2020 · 3 investors · BiotechnologyRule 506(b)
▶$63KraisedNov 2020 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Elliot GoldsteinExecutive Officer, Director
- Eugene WilliamsExecutive Officer, Director
- William WymanDirector
- Johannes RothDirector
- Patrick KirwinDirector
- Neil CashmanExecutive Officer, Director
- Richard GregoryDirector
- Steven PlotkinExecutive Officer
- Daniel E. GeffkenExecutive Officer
- Johanne KaplanExecutive Officer
- James KupiecExecutive Officer
- Offering amount
- $147.2K
- Amount sold
- $63K
- First sale
- Nov 2020
- Incorporated
- Corporation, Canada (federal Level)
- Federal exemptions
- 06b
▶$100KraisedNov 2019 · 1 investors · BiotechnologyRule 506(b)
▶$100KraisedNov 2019 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Eugene WilliamsExecutive Officer, Director
- Elliot GoldsteinExecutive Officer, Director
- Anthony GiovinazzoDirector
- Richard GregoryDirector
- Neil CashmanExecutive Officer, Director
- James KupiecExecutive Officer
- Johannes RothDirector
- William WymanDirector
- Johanne KaplanExecutive Officer
- Daniel E. GeffkenExecutive Officer
- Patrick KirwinDirector
- Offering amount
- $273.3K
- Amount sold
- $100K
- First sale
- Nov 2019
- Incorporated
- Corporation, Canada (federal Level)
- Federal exemptions
- 06b
▶$119.4KraisedJan 2019 · 4 investors · BiotechnologyRule 506(b)
▶$119.4KraisedJan 2019 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Daniel E. GeffkenExecutive Officer
- Elliot GoldsteinExecutive Officer, Director
- Neil CashmanExecutive Officer, Director
- Patrick KirwinDirector
- Eugene WilliamsExecutive Officer, Director
- Richard GregoryDirector
- William WymanDirector
- Johanne KaplanExecutive Officer
- Johannes RothDirector
- Anthony GiovinazzoDirector
- Offering amount
- $367.9K
- Amount sold
- $119.4K
- First sale
- Jan 2019
- Incorporated
- Corporation, Canada (federal Level)
- Federal exemptions
- 06b
▶$1.7MraisedMay 2018 · 18 investors · BiotechnologyRule 506(b)
▶$1.7MraisedMay 2018 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Anthony GiovinazzoDirector
- Daniel E. GeffkenExecutive Officer
- Patrick KirwinDirector
- Johanne KaplanExecutive Officer
- Richard GregoryDirector
- Neil CashmanExecutive Officer, Director
- Johannes RothDirector
- Eugene WilliamsExecutive Officer, Director
- Elliot GoldsteinExecutive Officer, Director
- William WymanDirector
- Offering amount
- $2.8M
- Amount sold
- $1.7M
- Sales commissions
- $64.8K
- Placement agents
- Noble Capital Markets, Inc.
- First sale
- Apr 2018
- Incorporated
- Corporation, Canada (federal Level)
- Federal exemptions
- 06b
▶$704.1KraisedSep 2017 · 15 investors · BiotechnologyRule 506(b)
▶$704.1KraisedSep 2017 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Anthony GiovinazzoDirector
- Johannes RothDirector
- Johanne KaplanExecutive Officer
- Richard GregoryDirector
- Patrick D. KirwinDirector
- Neil CashmanExecutive Officer, Director
- Janet ClennettExecutive Officer
- Elliot GoldsteinExecutive Officer, Director
- William WymanDirector
- Eugene WilliamsExecutive Officer, Director
- Offering amount
- $1.1M
- Amount sold
- $704.1K
- Sales commissions
- $44.1K
- Placement agents
- Noble Capital Markets, Inc.
- First sale
- Aug 2017
- Incorporated
- Corporation, Canada (federal Level)
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 8
TradingViewTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
PublicPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
StockTwitsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Simply Wall StSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
PerplexityAn AI-powered answer engine providing accurate, trusted, and real-time answers to questions.
Companies working in the same space as ProMIS Neurosciences.
In the news
Frequently asked questions
- What does ProMIS Neurosciences do?
- ProMIS Neurosciences is a clinical-stage biotechnology company developing antibody therapeutics that target toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's, ALS, and Parkinson's. The company operates in the biotechnology and neurology therapeutics space.
- Who founded ProMIS Neurosciences?
- ProMIS Neurosciences was founded by Neil Cashman, M.D..
- Who are ProMIS Neurosciences's investors?
- ProMIS Neurosciences's investors include Ally Bridge Group, Wellington Management.
- How much funding has ProMIS Neurosciences raised?
- ProMIS Neurosciences has disclosed $38.3M raised across 21 of its 22 known rounds.
- Where is ProMIS Neurosciences headquartered?
- ProMIS Neurosciences is headquartered in Toronto, CA.